Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024-Reference-Cited by-同舟云学术

Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024

Published:2024-02-22 Issue:8 Volume:29 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Maurel Marine¹,Howard Jennifer¹,Kissling Esther¹^ORCID,Pozo Francisco²³,Pérez-Gimeno Gloria⁴²,Buda Silke⁵,Sève Noémie⁶,McKenna Adele⁷,Meijer Adam⁸^ORCID,Rodrigues Ana Paula⁹,Martínez-Baz Iván¹⁰^ORCID,Mlinarić Ivan¹¹^ORCID,Latorre-Margalef Neus¹²,Túri Gergő¹³^ORCID,Lazăr Mihaela¹⁴,Mazagatos Clara⁴²,Echeverria Aitziber¹⁰,Abela Stephen¹⁵,Bourgeois Marc¹⁶,Machado Ausenda⁹^ORCID,Dürrwald Ralf¹⁷,Petrović Goranka¹¹^ORCID,Oroszi Beatrix¹³^ORCID,Jancoriene Ligita¹⁸,Marin Alexandru¹⁹,Husa Petr²⁰^ORCID,Duffy Roisin⁷,Dijkstra Frederika⁸,Gallardo García Virtudes²¹,Goerlitz Luise⁵,Enouf Vincent²²,Bennett Charlene²³,Hooiveld Mariëtte²⁴,Guiomar Raquel²⁵^ORCID,Trobajo-Sanmartín Camino¹⁰^ORCID,Višekruna Vučina Vesna¹¹^ORCID,Samuelsson Hagey Tove¹²,Lameiras Azevedo Ana Sofía²⁶,Castilla Jesús¹⁰^ORCID,Xuereb Gerd²⁷¹⁵,Delaere Bénédicte¹⁶,Gómez Verónica⁹,Tolksdorf Kristin⁵,Bacci Sabrina²⁸,Nicolay Nathalie²⁸,Kaczmarek Marlena²⁸,Rose Angela MC¹^ORCID,

Affiliation:

1. Epiconcept, Paris, France

2. CIBER de Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain

3. National Centre for Microbiology, National Influenza Reference Laboratory, WHO-National Influenza Centre, Institute of Health Carlos III, Madrid, Spain

4. National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain

5. Department for Infectious Disease Epidemiology, Respiratory Infections Unit, Robert Koch Institute, Berlin, Germany

6. Sorbonne Université, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France

7. HSE Health Protection Surveillance Centre, Dublin, Ireland

8. National Institute for Public Health and the Environment, Centre for Infectious Diseases Control, Bilthoven, the Netherlands

9. Epidemiology Department, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal

10. Instituto de Salud Pública de Navarra – IdiSNA – CIBERESP, Pamplona, Spain

11. Croatian Institute of Public Health, Zagreb, Croatia

12. Public Health Agency of Sweden, Stockholm, Sweden

13. National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary

14. Cantacuzino National Military Medical Institute for Research and Development, Bucharest, Romania

15. Infectious Disease Prevention and Control Unit (IDCU), Health Promotion and Disease Prevention, Msida, Malta

16. Department of Infectious Diseases, CHU UCL Namur (site Godinne), Université catholique de Louvain, Yvoir, Belgium

17. National Reference Centre for Influenza, Robert Koch Institute, Berlin, Germany

18. Clinic of Infectious Diseases and Dermatovenerology, Institute of Clinical Medicine, Medical Faculty, Vilnius University, Vilnius, Lithuania

19. Dr Victor Babes Clinical Hospital of Infectious and Tropical Diseases, Bucharest, Romania

20. University Hospital Brno and Masaryk University, Brno, Czechia

21. Servicio de Vigilancia y Salud Laboral, Dirección General de Salud Pública y Ordenación Farmacéutica, Consejería de Salud y Consumo, Andalucía, Spain

22. Centre National de Référence Virus des Infections Respiratoire (CNR VIR), Institut Pasteur Université Paris Cité, Paris, France

23. National Virus Reference Laboratory, University College Dublin, Dublin, Ireland

24. Nivel, Utrecht, the Netherlands

25. Laboratório Nacional Referência Gripe e outros Vírus Respiratórios, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal

26. Servicio de vigilancia y control epidemiológico, Subdirección general de Epidemiología y Vigilancia de la Salud, Dirección General de Salud pública, Valencia, Spain

27. Department of Child and Adolescent Health, Mater Dei Hospital, Msida, Malta

28. European Centre for Disease Prevention and Control, Stockholm, Sweden

Abstract

Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: −3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: −32 to 43), respectively.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Reference13 articles.

1. European Centre for Disease Prevention and Control (ECDC). European Respiratory Virus Surveillance Summary (ERVISS), 2024, Week 05. Stockholm: ECDC. [Accessed: 16 Feb 2024]. Available from: https://erviss.org

2. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2023-2024 northern hemisphere influenza season. Geneva: WHO; 2023. Available from: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2023-2024-northern-hemisphere-influenza-season

3. European Centre for Disease Prevention and Control (ECDC). Vaccine Scheduler. Stockholm: ECDC. [Accessed: 31 Jan 2024]. Available from: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=15&SelectedCountryIdByDisease=-1

4. European Centre for Disease Prevention and Control (ECDC). Core protocol for ECDC studies of vaccine effectiveness against symptomatic laboratory-confirmed influenza or SARS-CoV-2 infection at primary care level: version 1.0, September 2023. Stockholm: ECDC; 2023. Available from: https://data.europa.eu/doi/10.2900/25966

5. European Centre for Disease Prevention and Control (ECDC). Core protocol for ECDC VEBIS studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2 or seasonal influenza - Version 2.0. Stockholm: ECDC; 2023. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-vaccine-effectiveness-sari-protocol-version-2.pdf

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of inactivated influenza vaccine in children during the 2023/24 season: The first season after relaxation of intensive COVID-19 measures;Vaccine;2024-10

2. Influenza epidemiology and vaccine effectiveness during the 2023/2024 season in Italy: A test-negative case-control study;International Journal of Infectious Diseases;2024-10

3. Influenza vaccine effectiveness against influenza-associated hospitalizations in children, Hong Kong, November 2023 to June 2024;2024-08-30

4. Population-Based Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Infection in Southern China, 2023–2024 Season;Open Forum Infectious Diseases;2024-08-21

5. Vacunación frente a la gripe estacional en la infancia y la adolescencia. Recomendaciones del Comité Asesor de Vacunas e Inmunizaciones de la Asociación Española de Pediatría (CAV-AEP) para la temporada 2024-2025;Anales de Pediatría;2024-06